Lauren Lance
Primary Care · Pocahontas, ARNPI 1982228995
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $569 and has fallen 86.6% since, to $76 in 2025.
Across 56 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$127
- Biohaven Pharmaceutical Holding Company Ltd.$87
- AstraZeneca$85
- GSK$78
- Boehringer Ingelheim$70
- Johnson & Johnson$53
- plus $413 from 16 others
What the payments were for
- Food & beverage$912100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 9 | $127 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $87 |
| AstraZeneca | 6 | $85 |
| GSK | 4 | $78 |
| Boehringer Ingelheim | 5 | $70 |
| Johnson & Johnson | 4 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $52 |
| AbbVie | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Bayer | 3 | $43 |
| Pfizer | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $29 |
| Mylan Specialty L.p. | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
| Amgen | 1 | $12 |
How this compares
$912 in reported general payments places this provider in the 70th percentile of 76 primary care providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 50 | $50,257 |
| OzempicSemaglutide | 27 | $33,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $25,599 |
| EliquisApixaban | 25 | $17,509 |
| LinzessLinaclotide | 31 | $15,373 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $15,178 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $14,923 |
| JardianceEmpagliflozin | 24 | $13,882 |
| FarxigaDapagliflozin Propanediol | 22 | $11,740 |
| JanuviaSitagliptin Phosphate | 12 | $6,515 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $6,031 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,738 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $2,033 |
| Gabapentin | 112 | $1,732 |
| Atorvastatin Calcium | 188 | $1,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $14 | $50,25750 claims |
| Novo NordiskOzempic | $13 | $33,82127 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $85 | $30,65558 claims |
| GSKTrelegy Ellipta | $78 | $25,59939 claims |
| PfizerEliquis | $39 | $17,50925 claims |
| AbbVieLinzess | $48 | $15,37331 claims |
| Boehringer IngelheimJardiance | $70 | $13,88224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 76 primary care providers in Arkansas.
Other primary care in Pocahontas
- Andrew OliverMaumelle$45K
- Chelsea PressonLittle Rock$22K
- Stephen RohrerWynne$15K
- Chelsea MarquisSpringdale$12K
- Katherine ThompsonLittle Rock$10K
- Barbara ColeNorth Little Rock$9K
- Celeste WilliamsCenterton$6K
- Jennifer RogersCharleston$4K
- Meghan SkinnerSearcy$4K
- Krystalyn WilliamsLittle Rock$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.